These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37385233)

  • 1. Tolvaptan's Association with Low Risk of Acute Kidney Injury in Patients with Advanced Chronic Kidney Disease and Acute Decompensated Heart Failure.
    Tagaya T; Hayashi H; Ogata S; Takahashi K; Koide S; Inaguma D; Hasegawa M; Yuzawa Y; Tsuboi N
    Am J Nephrol; 2023; 54(7-8):319-328. PubMed ID: 37385233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.
    Ikeda S; Ohshima K; Miyazaki S; Kadota H; Shimizu H; Ogimoto A; Hamada M
    ESC Heart Fail; 2017 Nov; 4(4):614-622. PubMed ID: 29154417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
    Matsue Y; Suzuki M; Nagahori W; Yoshida K; Onishi Y; Satoh Y; Ono Y; Nishioka T; Noda M; Sugi K; Torii S; Tejima T; Sakurada H; Yamaguchi S; Okishige K; Fujii H; Takahashi A
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):73-7. PubMed ID: 24048511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial.
    Komiya S; Katsumata M; Ozawa M; Haze T; Kawano R; Ohki Y; Suzuki S; Kobayashi Y; Fujiwara A; Saka S; Tamura K; Hirawa N
    Clin Exp Nephrol; 2022 Sep; 26(9):851-858. PubMed ID: 35471469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure.
    Shirakabe A; Hata N; Yamamoto M; Kobayashi N; Shinada T; Tomita K; Tsurumi M; Matsushita M; Okazaki H; Yamamoto Y; Yokoyama S; Asai K; Shimizu W
    Circ J; 2014; 78(4):911-21. PubMed ID: 24553192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
    J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.
    Toda H; Nakamura K; Nakahama M; Wada T; Watanabe A; Hashimoto K; Terasaka R; Tokioka K; Nishii N; Miyoshi T; Kohno K; Kawai Y; Miyaji K; Koide Y; Tachibana M; Yoshioka R; Ito H;
    J Cardiol; 2016 Feb; 67(2):177-83. PubMed ID: 26072263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolvaptan in a pediatric patient with diuretic-resistant heart and kidney failure.
    Hirano D; Kakegawa D; Yamada A; Ito A; Miwa S; Ida H
    Pediatr Int; 2015; 57(1):183-5. PubMed ID: 25711263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study.
    Kida K; Shibagaki Y; Tominaga N; Matsumoto N; Akashi YJ; Miyake F; Kimura K
    Clin Pharmacokinet; 2015 Mar; 54(3):273-84. PubMed ID: 25305049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure.
    McCallum W; Tighiouart H; Testani JM; Griffin M; Konstam MA; Udelson JE; Sarnak MJ
    JACC Heart Fail; 2020 Jul; 8(7):537-547. PubMed ID: 32535124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population.
    Matsue Y; Suzuki M; Seya M; Iwatsuka R; Mizukami A; Nagahori W; Ohno M; Matsumura A; Hashimoto Y
    J Cardiol; 2013 Feb; 61(2):169-74. PubMed ID: 23159210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of adding nitroglycerin to early diuretic therapy on the morbidity and mortality of patients with chronic kidney disease presenting with acute decompensated heart failure.
    Aziz EF; Kukin M; Javed F; Pratap B; Sabharwal MS; Tormey D; Frankenberger O; Herzog E
    Hosp Pract (1995); 2011 Feb; 39(1):126-32. PubMed ID: 21441767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease.
    Ono Y; Takamatsu H; Inoue M; Mabuchi Y; Ueda T; Suzuki T; Kurabayashi M
    Drug Discov Ther; 2018; 12(3):154-160. PubMed ID: 29998996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Long-Term Treatment With Tolvaptan to Prolong the Time Until Dialysis Initiation in Patients With Chronic Kidney Disease and Heart Failure.
    Tanaka A; Hiramatsu E; Watanabe Y; Ito C; Shinjo H; Otsuka Y; Takeda A
    Ther Apher Dial; 2019 Aug; 23(4):319-327. PubMed ID: 30569597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.